Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRTCNASDAQ:MDXGNASDAQ:SLNONASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRTCiRhythm Technologies$142.37-0.3%$140.71$55.92▼$157.13$4.55B1.41482,173 shs206,877 shsMDXGMiMedx Group$6.29+0.9%$6.50$5.47▼$10.14$936.43M1.76674,419 shs319,320 shsSLNOSoleno Therapeutics$86.64+0.5%$77.90$40.19▼$87.16$4.37B-2.63789,814 shs330,112 shsTMDXTransMedics Group$128.73+0.8%$122.32$55.00▼$177.37$4.37B2.061.37 million shs369,545 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRTCiRhythm Technologies0.00%-7.98%-1.02%+41.88%+47.13%MDXGMiMedx Group0.00%+5.81%-2.10%-10.98%-7.84%SLNOSoleno Therapeutics0.00%+4.07%+12.45%+28.39%+106.13%TMDXTransMedics Group0.00%-2.07%-0.84%+90.22%-13.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRTCiRhythm Technologies1.0809 of 5 stars2.51.00.00.02.00.80.6MDXGMiMedx Group3.4471 of 5 stars3.53.00.00.00.63.31.9SLNOSoleno Therapeutics4.3805 of 5 stars3.52.00.04.62.72.50.6TMDXTransMedics Group1.6277 of 5 stars1.42.00.00.02.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRTCiRhythm Technologies 2.90Moderate Buy$138.60-2.64% DownsideMDXGMiMedx Group 3.00Buy$12.5098.89% UpsideSLNOSoleno Therapeutics 3.09Buy$107.1023.62% UpsideTMDXTransMedics Group 2.80Moderate Buy$127.33-1.08% DownsideCurrent Analyst Ratings BreakdownLatest MDXG, SLNO, IRTC, and TMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/17/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.006/17/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/11/2025IRTCiRhythm TechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $160.006/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRTCiRhythm Technologies$591.84M7.68N/AN/A$2.90 per share49.09MDXGMiMedx Group$348.88M2.66$0.33 per share19.14$1.31 per share4.80SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ATMDXTransMedics Group$441.54M9.86$1.64 per share78.52$6.81 per share18.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRTCiRhythm Technologies-$113.29M-$3.14N/AN/AN/A-15.90%-101.04%-9.55%7/30/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2723.2819.64N/A11.40%22.70%16.77%7/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)TMDXTransMedics Group$35.46M$1.3694.6590.02N/A10.03%21.88%6.15%7/30/2025 (Estimated)Latest MDXG, SLNO, IRTC, and TMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025MDXGMiMedx Group$0.06N/AN/AN/A$90.79 millionN/A7/30/2025Q2 2025TMDXTransMedics Group$0.48N/AN/AN/A$146.64 millionN/A5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/A5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million4/30/2025Q1 2025MDXGMiMedx Group$0.06$0.06N/A$0.05$86.32 million$88.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRTCiRhythm TechnologiesN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRTCiRhythm Technologies7.475.715.58MDXGMiMedx Group0.094.704.13SLNOSoleno Therapeutics0.2119.6419.64TMDXTransMedics Group1.929.108.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRTCiRhythm TechnologiesN/AMDXGMiMedx Group79.15%SLNOSoleno Therapeutics97.42%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipIRTCiRhythm Technologies1.10%MDXGMiMedx Group1.70%SLNOSoleno Therapeutics6.40%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRTCiRhythm Technologies2,00031.92 million31.57 millionOptionableMDXGMiMedx Group870147.70 million145.19 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableTMDXTransMedics Group21033.82 million31.46 millionOptionableMDXG, SLNO, IRTC, and TMDX HeadlinesRecent News About These CompaniesTransMedics Group, Inc. (TMDX) Cash Flow - Yahoo Finance4 hours ago | finance.yahoo.comIs TransMedics Stock a Buy After Short-Seller Drama?July 3 at 8:13 PM | fool.comTMDX - TransMedics Group Inc Key Metrics - MorningstarJuly 3 at 7:15 PM | morningstar.comMJanney Montgomery Scott LLC Has $592,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)July 3 at 3:34 AM | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Peregrine Capital Management LLCJuly 2 at 5:25 AM | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Taylor Frigon Capital Management LLCJune 30, 2025 | marketbeat.com2 Stocks That Have Doubled This Year and Are Still Worth BuyingJune 30, 2025 | fool.com28,870 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Lisanti Capital Growth LLCJune 29, 2025 | marketbeat.comPerigon Wealth Management LLC Purchases 4,543 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)June 29, 2025 | marketbeat.comTMDX - TransMedics Group Inc Sustainability - MorningstarJune 27, 2025 | morningstar.comMTransMedics Group Inc. (TMDX) Stock Price Today - WSJJune 26, 2025 | wsj.comReasons to Retain TransMedics Stock in Your Portfolio for NowJune 26, 2025 | zacks.comGlobal Assets Advisory LLC Invests $1.05 Million in TransMedics Group, Inc. (NASDAQ:TMDX)June 25, 2025 | marketbeat.comOppenheimer & Co. Inc. Has $5.25 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 25, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Solid Biosciences (SLDB) and Novo Nordisk (NVO)June 24, 2025 | theglobeandmail.comOppenheimer Raises TransMedics (TMDX) PT to $150 Following Key OrganOx Metra Label UpdateJune 24, 2025 | msn.comTransMedics' Turnaround: The Organ Transplant Leader Is Still A BuyJune 23, 2025 | seekingalpha.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cornerstone Wealth Management LLCJune 21, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by SG Americas Securities LLCJune 19, 2025 | marketbeat.comBoasting A 18% Return On Equity, Is TransMedics Group, Inc. (NASDAQ:TMDX) A Top Quality Stock?June 18, 2025 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 4.9% - Should You Sell?June 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayMDXG, SLNO, IRTC, and TMDX Company DescriptionsiRhythm Technologies NASDAQ:IRTC$142.36 -0.42 (-0.29%) Closing price 07/3/2025 03:37 PM EasternExtended Trading$142.36 0.00 (0.00%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.MiMedx Group NASDAQ:MDXG$6.28 +0.06 (+0.88%) Closing price 07/3/2025 03:00 PM EasternExtended Trading$6.16 -0.12 (-1.91%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Soleno Therapeutics NASDAQ:SLNO$86.64 +0.43 (+0.49%) Closing price 07/3/2025 02:34 PM EasternExtended Trading$86.64 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.TransMedics Group NASDAQ:TMDX$128.72 +1.04 (+0.81%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$127.15 -1.57 (-1.22%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
